EGFR and non-small cell lung carcinoma: Approximately 20-40% of non-small-cell lung cancer (NSCLC) patients harbor epidermal growth factor receptor mutations (EGFRm), primarily consisting of exon 19 deletions and exon 21 p.L858R (L858R) mutations (1).